DiaMedica Therapeutics Inc (NASDAQ:DMAC) – Investment analysts at Dougherty & Co issued their Q3 2019 earnings estimates for DiaMedica Therapeutics in a research note issued to investors on Thursday, August 15th. Dougherty & Co analyst K. Bauser forecasts that the company will earn ($0.19) per share for the quarter. Dougherty & Co has a “Buy” rating and a $8.00 price objective on the stock. Dougherty & Co also issued estimates for DiaMedica Therapeutics’ FY2019 earnings at ($0.91) EPS and FY2020 earnings at ($0.86) EPS.
DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.07.
NASDAQ DMAC opened at $2.64 on Monday. DiaMedica Therapeutics has a 52-week low of $2.21 and a 52-week high of $5.93. The firm has a 50-day moving average price of $3.68 and a 200 day moving average price of $3.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.96 and a quick ratio of 12.96.
A number of institutional investors have recently modified their holdings of the business. Worth Venture Partners LLC boosted its position in DiaMedica Therapeutics by 10.6% during the second quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock worth $657,000 after acquiring an additional 12,651 shares during the last quarter. Vanguard Group Inc. acquired a new stake in DiaMedica Therapeutics during the second quarter worth approximately $170,000. BlackRock Inc. boosted its position in DiaMedica Therapeutics by 159.7% during the second quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after acquiring an additional 16,651 shares during the last quarter. Granite Point Capital Management L.P. acquired a new stake in DiaMedica Therapeutics during the second quarter worth approximately $1,141,000. Finally, Eidelman Virant Capital acquired a new stake in DiaMedica Therapeutics during the second quarter worth approximately $173,000. 8.73% of the stock is owned by institutional investors.
In related news, Director Richard D. Pilnik bought 19,000 shares of the company’s stock in a transaction on Friday, May 31st. The stock was bought at an average cost of $2.80 per share, with a total value of $53,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders acquired 34,840 shares of company stock valued at $95,000. 12.80% of the stock is currently owned by corporate insiders.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Read More: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.